Table 1.
Characteristic | Median (inter-quartile range) or % |
---|---|
| |
Date of HAART initiation | February 1998 (March 1997, February 2000) |
| |
Cumulative NRTI use-years | 3.3 (1.6, 5.1) |
| |
Cumulative zidovudine use-years | 1.0 (0.5, 1.9) |
| |
Cumulative stavudine use-years | 0.5 (0.0, 1.0) |
| |
Cumulative abacavir use-years | 0.0 (0.0, 0.0) |
| |
Cumulative tenofovir use-years | 0.0(0.0, 0.0) |
| |
Cumulative PI use-years | 0.5 (0.2, 0.6) |
| |
Cumulative NNRTI use-years | 0.0 (0.0, 0.4) |
| |
Enrollment Period 1994–1995 | 91% |
| |
Age, yearsa | 38.7 (33.6,44.1) |
| |
Race/Ethnicity | |
African-American | 56% |
Hispanic | 25% |
White | 16% |
Other | 2% |
| |
Alcohol Use ≥3 drinks/weeka | 18% |
| |
Cigarette Smokinga | |
Current | 51% |
Former | 22% |
Never | 27% |
| |
Marijuana usesince last visit | 18% |
| |
Injection drug, heroin, cocaine, or crack use since last visit | 13% |
| |
Quality of Lifea | 65.5 (48.4, 79.5) |
| |
CESD ≥ 16a | 49% |
| |
Highest education level attained | |
Graduated college or higher | 8% |
Some College | 25% |
Completed High School | 31% |
Did not complete high school | 37% |
| |
Have AIDSa | 40% |
| |
CD4 cell count, cells/mm3a | |
<100 | 15% |
100–<200 | 18% |
200–<500 | 51% |
≥ 500 | 15% |
| |
log10HIVRNA, copies/mla | 4.2 (3.3, 4.8) |
ascertained from visit immediately prior to initiating HAART